Manufacturing Process Scale-Up For Phase III
Source: Thermo Fisher Scientific
By Sanjay Konagurthu, PhD, Senior Director, Science and Innovation, Thermo Fisher Scientific; John W. Burke, Manager of Pharmaceutical Process Technologies, Steriles, Thermo Fisher Scientific

Your compound has been progressing well through small-scale studies. The data collected in early trials suggest the formulation is safe and has great potential for improving its intended target condition. Critical make-or-break Phase III studies are on the horizon to demonstrate safety and efficacy in large numbers of patients. Is your team ready to manufacture larger batch sizes to support this endeavor? Possibly.
access the White Paper!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.
Subscribe to Pharmaceutical Online
X
Subscribe to Pharmaceutical Online
Thermo Fisher Scientific
This website uses cookies to ensure you get the best experience on our website. Learn more